Strides Shasun Gets USFDA Approval For Parkinsons Drug
New Delhi: Strides Shasun said it has received approval from the US health regulator for Amantadine Hydrochloride, used for the treatment of Parkinsons disease and select viral infections, in the American market.
"The product has received approval in 15 months under the USFDA's new product clearance regime of GDUFA. The product will be launched immediately," Strides Shasun said in a BSE filing.
Amantadine Hydrochloride is used for the treatment of Parkinsons disease and Shingles (Herpes Zoster) to reduce pain.
Quoting IMS data, Strides Shasun said the US market for Amantadine Hydrochloride is approximately $25 million with three generic players.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd